Thai-Made Cancer Drugs Added to Gold Card Coverage
Thai-manufactured cancer drugs including targeted therapies and biosimilars have been approved for coverage under the Gold Card national health insurance scheme, expanding affordable access to high-efficacy treatments previously dominated b
Good news for cancer patients: Thailand's health insurance board has approved innovative Thai-manufactured cancer medications for inclusion in the National Health Security Scheme, commonly known as the 30-baht Gold Card. On July 6, Health Minister Pattana Prommapatt, chairman of the National Health Security Board, announced the board's approval to support the use of cancer medications from Thailand's Innovation List, produced by Chulabhorn Royal Academy and Chulabhorn Research Institute, under the national health insurance system. This initiative aims to expand access to high-efficacy cancer treatments equitably and affordably.
Pattana stressed the decision's importance to Thailand's healthcare system, as cancer remains a major health challenge for Thai citizens. High-efficacy cancer drugs, particularly targeted therapies and biological medications, remain expensive, and Thailand has relied heavily on imports. Developing domestic production capacity is a critical step in strengthening Thailand's health system, improving patient care, managing budgets, and ensuring long-term drug security.
The cancer drug development stems from the vision of Princess Chulabhorn Walailak, who recognized the importance of ensuring equitable access to high-quality, affordable cancer treatment while building Thailand's pharmaceutical research and production capabilities. This aligns with the national health insurance system's goal of providing essential healthcare services to all citizens without exclusion.
Pattana explained that the approved cancer medications include small-molecule targeted therapies produced by Chulabhorn Royal Academy, such as Imcranib (containing imatinib) and Gefcranib (containing gefitinib), developed in the royal medicine factory. Chulabhorn Research Institute has developed biosimilar medications including Herdara (containing trastuzumab), established at the biological research and development center.
The board also approved a three-year advance procurement plan between Chulabhorn Royal Academy, Chulabhorn Research Institute, and the National Health Security Office. This enables continuous production planning, price control, efficient budget management, and full-capacity purchasing support aligned with system needs.